{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:21:35Z","timestamp":1780392095120,"version":"3.54.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Over the years when disease-modifying antirheumatic drugs (DMARDs) have been used in rheumatoid arthritis patients, reports of malignancies have emerged. This study aims to investigate the association between malignancies and DMARDs by using data extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>FAERS data (January 2019 to December 2023) were reviewed. For each drug-event pair, the disproportionality analysis was conducted to evaluate the risk of malignancy. Multivariate logistic regression was implemented to mitigate potential biases. Moreover, the time to onset of malignancy was also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We conducted a detailed search for rheumatoid arthritis indications and identified a total of 17,412 adverse event reports associated with malignancies, with selective DMARDs designated as the role code \u201cprimary suspect\u201d. At the preferred term level, there were 198 positive signals, among which the lower limit of the 95% confidence interval for the information component is 3.55 for squamous cell carcinoma of the skin, 2.39 for breast cancer, and 2.27 for lymphoproliferative disorder. In comparison to other DMARDs, targeted synthetic DMARDs were associated with a broader range of malignancies at both preferred term and Standardized MedDRA Queries levels. The number of adverse events reported in female patients is approximately 2\u20133 times higher than men, and the median age across the population was approximately 62\u00a0years. In terms of onset time, the conventional synthetic DMRADs exhibited a relatively longer median time, ranging from 3.58 to 7.08\u00a0years, while the targeted synthetic DMARDs demonstrated a shorter median time of 0.83\u20131.67\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study uncovers varying degrees of malignancy risks related to DMARDs, with a significantly higher risk observed in targeted synthetic DMARDs. Additionally, novel malignancy signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1458500","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:15:50Z","timestamp":1731496550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Wan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gefei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti\u2010HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.psychres.2023.115300","article-title":"Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS","volume":"326","author":"Chen","year":"2023","journal-title":"Psychiatry Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","article-title":"The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches","volume":"43","author":"Cruceriu","year":"2020","journal-title":"Cell. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41584-020-0503-4","article-title":"Sex steroids and autoimmune rheumatic diseases: state of the art","volume":"16","author":"Cutolo","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2407-12-24","article-title":"Nkg2d ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study","volume":"12","author":"De Kruijf","year":"2012","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.4049\/jimmunol.177.11.8046","article-title":"The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor","volume":"177","author":"Devoogdt","year":"2006","journal-title":"J. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B14","unstructured":"FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine prolia (denosumab)"},{"key":"B15","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions"},{"key":"B16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1158\/2159-8290.Cd-15-0732","article-title":"STAT5 is a key regulator in nk cells and acts as a molecular switch from tumor surveillance to tumor promotion","volume":"6","author":"Gotthardt","year":"2016","journal-title":"Cancer Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/1756-185x.13028","article-title":"Burden of rheumatoid arthritis from a societal perspective: a prevalence-based study on cost of this illness for patients in China","volume":"21","author":"Hu","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/s0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isom\u00e4ki","year":"1978","journal-title":"J. Chronic Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"Jain","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.4049\/jimmunol.163.10.5358","article-title":"Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells","volume":"163","author":"Kashii","year":"1999","journal-title":"J. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00002018-199920060-00002","article-title":"Lymphoma in patients with rheumatoid arthritis what is the evidence of a link with methotrexate","volume":"20","author":"L","year":"1999","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","article-title":"Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity","volume":"62","author":"Meudec","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ajh.21003","article-title":"Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection","volume":"82","author":"Miyazaki","year":"2007","journal-title":"Am. J. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3892\/ijo.30.4.803","article-title":"TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma","volume":"30","author":"Nakagawa","year":"2007","journal-title":"Int. J. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e33293","DOI":"10.7759\/cureus.33293","article-title":"The role of biologics in rheumatoid arthritis: a narrative review","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.rdc.2020.05.003","article-title":"Cancer and rheumatoid arthritis","volume":"46","author":"Pundole","year":"2020","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological dmards: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.1158\/0008-5472.CAN-07-1599","article-title":"Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response","volume":"19","author":"Seynhaeve","year":"2007","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/BOR.0000000000000796","article-title":"Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence","volume":"33","author":"Singh","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40264-024-01461-1","article-title":"A systematic overview of contraindications and special warnings for biologic and targeted synthetic disease modifying antirheumatic drugs: establishing a framework to create a \u201cSafety Checklist\u201d","volume":"47","author":"Skaarup","year":"2024","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/rheumatology\/keq301","article-title":"Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three european biologics registers","volume":"50","author":"Strangfeld","year":"2010","journal-title":"Rheumatol. Oxf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1073\/pnas.0708594105","article-title":"Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis","volume":"105","author":"Swann","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1067\/mtc.2001.113026","article-title":"The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma","volume":"121","author":"Takanami","year":"2001","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: an updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-018-0774-9","article-title":"A practical approach to the use of conventional synthetic, biologic and targeted synthetic disease modifying anti-rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy","volume":"20","author":"Wong","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1050876","DOI":"10.3389\/fimmu.2022.1050876","article-title":"Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: will immunosuppressants work?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:15:56Z","timestamp":1731496556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":47,"alternative-id":["10.3389\/fphar.2024.1458500"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1458500","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"1458500"}}